11q Deletion Is Not a Prognostic Factor for Ad... - CLL Support
11q Deletion Is Not a Prognostic Factor for Adverse Outcomes for Patients with CLL treated with ibrutinib
You need to be a member of this community to see this post.
Read more about...
3 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Updated Results: Combined Ibrutinib and Venetoclax for 1st lineTreatment for CLL
Michael J Keating et al Dec 2019 - ASH oral presentation
Here they report updated data for the 80...
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies
10th Feb 2019
Older age and higher comorbidity burden are associated with poor survival outcomes in...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Good News for our untreated Canadian members!
This latest approval is based on...
Related Posts
Five-year results for the iFCG regimen: first-line treatment of CLL patients with mutated IGHV and without del(17p)/TP53 mutation- Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
RICHTER'S TRANSFORMATION IN PATIENTS WITH CLL: ANALYSIS OF BIOLOGICAL AND CLINICAL RISK FACTORS AND OUTCOMES- Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
